31 March 2021 - NICE has published an evidence base recommendation on ribociclib succinate (Kisqali) for the treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer who have had previous endocrine therapy.

Ribociclib succinate, when used in combination with fulvestrant, is recommended as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy only if:

• exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, and
• Novartis provides ribociclib according to the commercial arrangement.

Read NICE technology appraisal guidance